Johnson & Johnson announced new analyses from the Phase 3 Vivacity-MG3 study demonstrating that IMAAVY (nipocalimab), an FcRn blocker, improves symptoms in adults with generalized myasthenia gravis (gMG), including those early in their disease or with lower symptom severity. The treatment showed sustained meaningful clinical improvement and maintained symptom control even after common infections, a known trigger for disease worsening. Additionally, the PETUNIA study will collect pregnancy safety data for IMAAVY, addressing current evidence gaps. IMAAVY is approved for adults and pediatric patients 12 years and older with antibody-positive gMG, offering a targeted approach to reduce pathogenic IgG autoantibodies driving the disease.
Vanguard High Dividend Yield Index Fund ETF (VYM) provides income through dividends from over 500 U.S. stocks, focusing on large, profitable companies like Broadcom and JPMorgan Chase. With a very low expense ratio of 0.04%, nearly all dividends are ...
The Vanguard Dividend Appreciation ETF (VIG) focuses on U.S. companies with at least 10 years of consecutive dividend increases, emphasizing quality and income durability rather than high yield. Its top holdings like Johnson & Johnson, Procter & Gamb...
The Schwab U.S. Dividend Equity ETF (SCHD) continues to deliver a reliable and growing dividend stream, supported by a portfolio of companies with long histories of dividend payments and strong cash flows. Key holdings like Coca-Cola, Chevron, and Lo...
Johnson & Johnson has increased its quarterly dividend by 3.1%, marking 64 consecutive years of dividend growth. The company’s strong cash flow, with nearly double coverage of its dividend payout, and accelerating revenue growth of 9.9% in Q1 2026 su...
The SNPD ETF targets companies with at least 10 years of consecutive dividend growth, blending established Dividend Kings with promising newer payers. Its top holdings include Johnson & Johnson, Procter & Gamble, Coca-Cola, Lowe’s, and PepsiCo, most ...
